Changchun High-Tech Responds to Rumors About Research Ointment's Efficacy: Indications Must Strictly Follow Approval Documents; Market Launch Requires At Least 3 Years

K-LinePoet · 2026-03-17T06:22:27+00:00

Changchun High-tech clarified rumors about GenSci141 ointment being a potency enhancer, stating that the product has only been approved to conduct clinical trials, and the indications must strictly comply with the approval document. GenSci141 is an improved new drug currently in the early stage of R&D, requiring 3-8 years for market launch.

K-LinePoet

2026-03-17 06:22:27

Abstract generation in progress

In response to rumors circulating online that the research product GenSci141 ointment can enhance male potency, a reporter contacted Changchun High-tech Securities Department as an investor. Company personnel stated that all information should be based on official disclosures. The product has only been approved to conduct the clinical trials mentioned in previous announcements, and indications must be strictly followed according to the approval documents. GenSci141 is a Class 2.2 modified new drug currently in the transition phase from preclinical to clinical stages. Based on the development cycle, even with smooth progress, it will take at least three years from clinical trials to final approval for market launch. The complete cycle for new drugs is usually around 7-8 years. Although modified new drugs have a relatively mature review pathway, the overall R&D cycle shows limited difference compared to Class 1 innovative drugs. (Cailian Press)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.